13-Nov-2024
Baupost's top Q3 trades include Jazz exit, new Dollar General stake
Seeking Alpha News (Wed, 13-Nov 5:36 PM ET)
J.P. Morgan Remains a Buy on Jazz Pharmaceuticals (JAZZ)
TipRanks (Mon, 11-Nov 7:17 AM ET)
TipRanks (Mon, 11-Nov 7:16 AM ET)
TipRanks (Mon, 11-Nov 3:10 AM ET)
Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
PRNewswire (Wed, 6-Nov 4:05 PM ET)
PRNewswire (Thu, 31-Oct 4:05 PM ET)
Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024
PRNewswire (Wed, 23-Oct 4:15 PM ET)
PRNewswire (Tue, 15-Oct 7:30 AM ET)
PRNewswire (Mon, 16-Sep 7:30 AM ET)
Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024
PRNewswire (Mon, 9-Sep 7:58 AM ET)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Jazz Pharmaceuticals PLC - trades on the NASDAQ stock market under the symbol JAZZ.
As of November 13, 2024, JAZZ stock price declined to $127.65 with 779,743 million shares trading.
JAZZ has a beta of 0.53, meaning it tends to be less sensitive to market movements. JAZZ has a correlation of 0.05 to the broad based SPY ETF.
JAZZ has a market cap of $7.88 billion. This is considered a Mid Cap stock.
Last quarter Jazz Pharmaceuticals PLC - reported $1 billion in Revenue and $6.61 earnings per share. This beat revenue expectation by $15 million and exceeded earnings estimates by $1.11.
In the last 3 years, JAZZ traded as high as $169.98 and as low as $99.06.
The top ETF exchange traded funds that JAZZ belongs to (by Net Assets): COWZ, IJH, VTI, VB, VBR.
JAZZ has underperformed the market in the last year with a return of +6.2%, while SPY returned +37.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in JAZZ shares. However, JAZZ has outperformed the market in the last 3 month and 2 week periods, returning +18.0% and +14.1%, while SPY returned +12.3% and +2.7%, respectively. This indicates JAZZ has been having a stronger performance recently.
JAZZ support price is $125.26 and resistance is $130.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JAZZ shares will trade within this expected range on the day.